Mayne Pharma Ltd (ASX: MYX) is an Australian specialist pharmaceutical company, creating commericialised and generic products you’ll find in pharmacies across Australia. Mayne Pharma’s history started in South Australia. Today, it develops most of its drugs in Australia and the USA.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -1.16% to 6900.70.
The Mayne Pharma Group Ltd (ASX: MYX) share price continues its decline, dropping by 8.47% today. The Mayne Pharma share price may get worse after posting ordinary FY21 results.
The Mayne Pharma Group Ltd (ASX: MYX) share price soared by 17% last Friday but has dropped slightly today. What’s happening with Mayne Pharma share price?
The Mayne Pharma Group Ltd (ASX: MYX) share price crashed 17% on Tuesday on negative news received from the FDA. Is this a buying opportunity for Mayne shares?
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.50% at lunch.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.02% at lunch.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 1.21% at lunch.
Is the Mayne Pharma Group Ltd (ASX:MYX) share price a buy after revealing a new supply agreement?
The ASX 200 (INDEXASX:XJO)(^AXJO) is expected to open lower today, the USA’s S&P 500 Index (.INX) fell by 1.23% on Tuesday.
